Doog,
Ideally, a biotech has a pipeline that targets a major market that can generate massive returns, and they usually have a lead product. Envisioned to deliver this pipeline to market, it is well funded and moving along nicely. That's what people wants to invest in.
The current NASH stocks like CNAT for example. Massive potential market, well funded, partnered, and moving along with trials this year. Naturally, stock tripled and might have bit more room to run higher.
the way I see it is that Odidi thinks he can pull this off one step at a time with limited budgets. You can tell by his own words. So maybe we don't see big developments in the next few years, but it seems like eventually we get there type of deal here. Again, I'm not saying Rexista has no value. I'm just saying to get to where we expect, might take far longer than we like.
Maybe he doesn't have much choice, since hostile take over isn't uncommon if some group wants his research. So he can be protective of his hard work. This isn't necessarily a good thing though.
I would rather see IPCI having the financial backing of deep pockets or billionaires to see this through. But, that's the thing is if somebody owns the shares, Odidi loses control of the company.
So cross fingers he makes a good deal on Rexista soon.
News 
Market Data 
Discover 
